ReShape Lifesciences Inc (RSLS) Stock
RSLS is no longer traded. ReShape Lifesciences was delisted from the Nasdaq in August 2025.
Prices on this page are historical; the last trade was August 14, 2025 at $3.92.
ReShape Lifesciences stock price history
RSLS final trading statistics
- Final close
- $3.92
- Final trading day
- Aug 14, 2025
- Market cap at delisting
- $9.35M
- Shares outstanding
- 2.39M
- Final 52-week range
- $0.11 – $12.13
- Avg. volume (final 3 mo.)
- 884,118
- All-time high (split-adj.)
- $1000000.00 · Oct 2016
- All-time low (split-adj.)
- $3.90 · Mar 2020
- Return since IPO
- -100.0%
- Beta
- 1.90
- Book value / share
- -$8.66
- Price / book
- -0.45
ReShape Lifesciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $8.01M | -$7.1M | — |
| FY2023 | $8.68M | -$11.4M | -$3.55 |
| FY2022 | $11.24M | -$46.2M | -$81.59 |
| FY2021 | $13.60M | -$61.9M | -$190.50 |
| FY2020 | $11.30M | -$21.6M | -$238.50 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is involved in the development of the ReShape Obalon Balloon System, which consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and the Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in Irvine, California.
ReShape Lifesciences stock FAQ
What happened to ReShape Lifesciences stock?
ReShape Lifesciences stock was delisted from the Nasdaq. Its final close was $3.92 on August 14, 2025.
Is RSLS stock still trading?
No. RSLS was delisted from the Nasdaq in August 2025 and no longer trades on a U.S. exchange.
What was the last price of RSLS stock?
RSLS closed at $3.92 on its final trading day, August 14, 2025, for a market value of about $9.35M.
What were ReShape Lifesciences's revenue and earnings in its last full fiscal year?
ReShape Lifesciences reported revenue of $8.01M and net income of -$7.1M in fiscal 2024, its last full year as a public company.
When did ReShape Lifesciences go public?
ReShape Lifesciences Inc stock began trading on November 15, 2007.